Introgen Therapeutics Announces Studies to Be Presented at the Upcoming 12th International Conference on Gene Therapy of Cancer.
AUSTIN, Texas, Dec. 9 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN) announced today its schedule of presentations and posters to be discussed in multiple scientific sessions at the 12th International Conference on Gene Therapy of Cancer taking place in San Diego, Calif. on December 11 - 13, 2003.
There will be four presentations including:
Thursday, December 11 at 10:00 a.m. (PST) -- "Mda-7/IL-24 Mediated
Killing of Human Ovarian Cancer Cells Involves the Fas/FasL Signaling
Pathway" presented by Dr. Rajagopal Ramesh, Assistant Professor,
Department of Thoracic and Cardiovascular Surgery at M.D. Anderson
Cancer Center. Preclinical data identify ovarian cancer as a novel
target for Introgen's INGN 241 and identify a novel molecular pathway
in these cells.
Thursday, December 11 at 10:30 a.m. (PST) -- "Mda-7 Gene Transfer
Exploits Multiple Molecular Pathways to Combat Cancer" presented by Dr.
Sunil Chada, Ph.D, Director of Research and Development at Introgen
Therapeutics Inc. Dr. Chada will review several key mechanisms
identified by Introgen and its collaborators by which mda-7/IL-24 gene
expression fights cancer. This presentation will highlight the broad
and multi-functional potential of INGN 241.
Friday, December 12 at 2:45 p.m. (PST) -- "Advenovirus Oncolytic
Vectors That Overexpress ADP" presented by Dr. William S.M. Wold,
Chairman of the Department of Molecular Microbiology and Immunology at
St. Louis University School of Medicine. Significant advances related
to the development of Introgen's oncolytic virus product candidate,
INGN 007, will be featured.
Friday, December 12 at 4:00 p.m. (PST) -- "Update on INGN 241 Clinical
Trial" presented by Dr. John Nemunaitis, Medical Director of U.S.
Oncology. A review and update on the safety, biologic and clinical
activity of Introgen's INGN 241 in patients with various tumor types
will be presented.
Additionally, there will be two poster sessions featuring Introgen's INGN 241 drug candidate on Thursday, December 11:
-- The Tumor Suppressor Activity of MDA-7/IL-24 is Mediated by
Intracellular Protein Expression in NSCLC
-- Ectopic Production of MDA-7/IL-24 Inhibits Invasion and Migration of
Human Lung Cancer Cells
These poster presentations discuss preclinical data which further defines Introgen's understanding of the mechanisms of action by which INGN 241 (Ad- mda-7) regulates the migration and death of lung cancer cells.
Introgen is a leading developer of biopharmaceutical products designed to induce therapeutic protein expression using non-integrating gene agents for the treatment of cancer and other diseases. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates a commercial-scale, CGMP manufacturing facility.
Certain statements in this press release that are not strictly historical may be "forward-looking" statements, which are based on current expectations and entail various risks and uncertainties. Such forward-looking statements include, but are not limited to, those relating to Introgen's future success with its clinical development program for the treatment of cancer or other diseases. There can be no assurance that Introgen will be able to commercially develop gene-based drugs, that necessary regulatory approvals will be obtained or that any clinical trials or studies undertaken will be successful or that the proposed treatments will prove to be safe and/or effective. The actual results may differ from those described in this press release due to risks and uncertainties that exist in Introgen's operations and business environment, including, but without limitation, Introgen's stage of product development and the limited experience in the development of gene- based drugs in general, Introgen's dependence upon proprietary technology and current competition, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed on March 31, 2003 and its quarterly report on Form 10-Q filed on November 14, 2003, and its prospectus supplement filed with the SEC pursuant to Rule 424(b)(2) on November 26, 2003. Introgen undertakes no obligation to publicly release the results of any revisions to any forward- looking statements that reflect events or circumstances arising after the date hereof.
Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: www.introgen.com .
Contact:
Introgen Therapeutics, Inc.
C. Channing Burke
(512) 708 9310 Ext. 322
Email: c.burke@introgen.com
SOURCE Introgen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc.,
512-708-9310, ext. 322, or c.burke@introgen.com
Web site: introgen |
